Patient‐reported outcomes in patients with non‐alcoholic fatty liver disease: A narrative review of Chronic Liver Disease Questionnaire‐non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis

医学 脂肪肝 脂肪性肝炎 内科学 胃肠病学 慢性肝病 疾病 肝硬化
作者
Sakura Yamamura,Dan Nakano,Ryuki Hashida,Tsubasa Tsutsumi,Takumi Kawaguchi,Michiaki Okada,Hiroshi Isoda,Hirokazu Takahashi,Hiroo Matsuse,Yuichiro Eguchi,Yoshio Sumida,Atsushi Nakajima,Lynn H. Gerber,Zobair M. Younossi,Takuji Torimura
出处
期刊:Journal of Gastroenterology and Hepatology [Wiley]
卷期号:36 (3): 629-636 被引量:34
标识
DOI:10.1111/jgh.15172
摘要

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide and one of the leading causes of hepatocellular carcinoma and liver transplantation. Moreover, patients with NAFLD frequently complain of non-specific symptoms including fatigue, abdominal discomfort, as well as anxiety, and NAFLD is reported to affect patient-reported outcomes (PROs). Thus, for clarifying the total burden of NAFLD, it is crucial to assess all associated outcomes, including not only clinical and economic outcomes but also PROs. PROs are thought to reflect what is happening in one's daily life and is an important way patients and health-care professionals communicate. There are various instruments for the assessment of PROs. Recently, a NAFLD/non-alcoholic steatohepatitis (NASH)-specific instrument called "Chronic Liver Disease Questionnaire (CLDQ)-NAFLD/NASH" has been developed. CLDQ-NAFLD/NASH comprises six domains: (i) abdominal symptoms, (ii) activity/energy, (iii) emotional health, (iv) fatigue, (v) systemic symptoms, and (vi) worry. CLDQ-NAFLD/NASH has demonstrated excellent internal consistency, face validity, content validity, and test-retest reliability. It has been sufficiently validated in two international phase 3 clinical trials. In this review, we summarize features of various instruments for assessing PROs by focusing on CLDQ-NAFLD/NASH. We also examine the validity of CLDQ-NAFLD/NASH in Japanese patients and alterations in CLDQ-NAFLD/NASH score in Japanese patients with significant hepatic fibrosis. Moreover, we discuss the utility of CLDQ-NAFLD/NASH in phase 3 clinical trials and in a real-world clinical setting.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
幽默的老师完成签到,获得积分10
刚刚
完美的冬瓜完成签到,获得积分10
刚刚
rimbaud完成签到,获得积分10
刚刚
1秒前
Hello的应助被风趣雪卉采纳,获得10
1秒前
1秒前
1秒前
FashionBoy的应助被Lizhe采纳,获得10
2秒前
2秒前
果粒橙完成签到,获得积分10
3秒前
3秒前
3秒前
汉堡包的应助被很拉风旅行包采纳,获得10
3秒前
青荣发布了新的文献求助10
3秒前
聪慧跳跳糖完成签到,获得积分10
4秒前
极限001的应助被晚风采纳,获得50
4秒前
orixero的应助被晚风采纳,获得10
4秒前
zsj发布了新的文献求助10
5秒前
七里香发布了新的文献求助10
5秒前
七七发布了新的文献求助10
5秒前
Crane发布了新的文献求助10
5秒前
lql完成签到,获得积分20
6秒前
6秒前
Tangerine发布了新的文献求助10
7秒前
7秒前
SZH完成签到,获得积分20
7秒前
ZHOU发布了新的文献求助10
8秒前
CarryLJR的应助被鹤鹤采纳,获得10
8秒前
8秒前
ghw发布了新的文献求助10
9秒前
Zero完成签到,获得积分10
9秒前
ling发布了新的文献求助10
10秒前
11秒前
研友_VZG7GZ的应助被nana采纳,获得10
11秒前
瀛洲晚风发布了新的文献求助10
11秒前
爆米花的应助被蒲公英采纳,获得10
12秒前
常威正在打来福完成签到,获得积分10
12秒前
七七完成签到,获得积分10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593